Originally published by our sister publication Gastroenterology & Endoscopy News
By Ted Bosworth
CHICAGO—In biologic-experienced patients with ulcerative colitis, tofacitinib and ustekinumab achieve about the same rate of corticosteroid-free remission by 16 weeks, according to research presented at Digestive Disease Week 2023.
However, despite similar rates of corticosteroid-free remission (CFR), primary failure to a biologic and treatment with three or more biologics were associated